CYBN Overview

Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.

Wall Street analysts forecast CYBN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYBN is45.00 USD with a low forecast of 30.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Cybin Inc revenue for the last quarter amounts to 0.00 USD, decreased

Cybin Inc. EPS for the last quarter amounts to -1.39 USD, decreased -33.81

Cybin Inc (CYBN) has 50 emplpoyees as of March 12 2026.

Today CYBN has the market capitalization of 200.95M USD.